E. J. Czerwiński

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Felicia Cosman, Daria B. Crittenden, Jonathan D. Adachi et al. · New England Journal of Medicine · 2016 · 1.7K citations · Full text

Medicine, Orthopedic Surgery, Pharmacotherapy +17

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

Henry G. Bone, Rachel B. Wagman, Maria Luisa Brandi et al. · The Lancet Diabetes & Endocrinology · 2017 · 961 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +12

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

Socrates E. Papapoulos, Roland Chapurlat, Cesar Libanati et al. · Journal of Bone and Mineral Research · 2011 · 344 citations · Full text

Medicine, Orthopaedic Surgery, Bone Metabolism +14